Companies reporting earnings this week included Tryg A/S, Barnes & Noble Education, Nurix Therapeutics, Enerpac Tool Group, and an unnamed group reporting 483.6 million euros in sales revenue. Tryg A/S reported 3.3 percent premium growth for Q2 2026 despite a one-off provision from a Danish Supreme Court ruling. Barnes & Noble Education achieved a financial turnaround with 16.9 million dollars in net income, while Nurix Therapeutics secured a 700 million dollar upfront payment through a collaboration with Roche. Enerpac Tool Group reported 168 million dollars in Q3 fiscal 2026 net sales, a 6 percent year-over-year increase, alongside an agreement to acquire SFE Group. Finally, the unnamed group saw a 3.4 percent increase in cumulative six-month profit before tax, reaching 1.4 million euros in net profit for the first half of 2026. Synthesized from 212 manifests produced by 2 monitored earnings-release sources in the last 7 days, including quarterly results, guidance updates.
Answer updated Jul 11, 2026 00:00 UTC · rebuilt twice daily from the rolling 168-hour window
Tryg A/S - interim report Q2 and H1 2026
Tryg A/S delivered strong commercial momentum in Q2 2026, characterized by 3.3% premium growth and improved underlying claims ratios. While reported profits were impacted by a one-off provision following an April 2026 Danish Supreme Court ruling on workers' compensation, adjusted results show year-over-year growth. The
Barnes & Noble Education Reports Full-Year Fiscal 2026 Financial Results
Barnes & Noble Education (BNED) achieved a significant financial turnaround in fiscal 2026, reporting $16.9 million in net income compared to a $65.8 million loss in the prior year. Growth was primarily driven by a 28% revenue increase in its BNC First Day programs and disciplined expense management. The company also s
Unaudited consolidated interim accounts for the second quarter and first six months of 2026
The Group demonstrated solid top-line growth in the first half of 2026, with sales revenue reaching 483.6 million euros, an 8.0% increase year-on-year. While second-quarter profit before tax saw a slight contraction of 7.2%, the cumulative six-month profit before tax grew by 3.4%. Net profit for the first half saw a si
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Nurix Therapeutics has secured a major global collaboration with Roche to co-develop and co-commercialize its BTK degrader, bexobrutideg, across oncology, immunology, and neurology. The deal includes a $700 million upfront payment and total potential milestones of $2.3 billion, significantly strengthening Nurix's finan
Enerpac Tool Group Reports Third Quarter Fiscal 2026 Results and Announces Acquisition of SFE Group
Enerpac Tool Group reported Q3 fiscal 2026 net sales of $168 million, a 6% increase year-over-year, and announced a definitive agreement to acquire SFE Group. While the company saw organic growth in its Industrial Tool & Service (IT&S) product segment, it faced service revenue declines and geopolitical headwinds. Conse